Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers

Gastrointestinal cancers (GI) account for 26% of cancer incidences globally and 35% of all cancer-related deaths. The main challenge is to target cancer specific antigens. Mucins are heavily O-glycosylated proteins overexpressed in different cancers. The transmembrane glycoprotein MUC1 is the most l...

Descripción completa

Detalles Bibliográficos
Autores principales: Bose, Mukulika, Mukherjee, Pinku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712407/
https://www.ncbi.nlm.nih.gov/pubmed/33167508
http://dx.doi.org/10.3390/vaccines8040659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712407/
https://www.ncbi.nlm.nih.gov/pubmed/33167508
http://dx.doi.org/10.3390/vaccines8040659

Ejemplares similares